Krystal Biotech's VYJUVEK: $88M Revenue, Global Expansion, Pipeline Advancements

Krystal Biotechs Q1 2025 earnings showcase impressive growth for VYJUVEK, their gene therapy for dystrophic epidermolysis bullosa, with a 95% increase in net revenue to $88.2 million and a solid 94% gross margin. The US launch has over 540 patients with reimbursement approvals, and global expansion is underway with a focus on the EU and Japan markets. Krystals pipeline is robust with four readouts planned this year, and recent publications support VYJUVEKs long-term safety and durable healing. With US manufacturing and profitable quarters, Krystal is well-positioned for global growth and shareholder wins. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/27049c491f5839c1